2013, Número 2
<< Anterior Siguiente >>
Ann Hepatol 2013; 12 (2)
Vitamin D deficiency and vitamin D therapy in chronic hepatitis C
Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, Rodrigo M, Estrada V, López-Alonso G, Agúndez JA
Idioma: Ingles.
Referencias bibliográficas: 23
Paginas: 199-204
Archivo PDF: 94.96 Kb.
RESUMEN
Sin resumen
REFERENCIAS (EN ESTE ARTÍCULO)
Gutierrez JA, Parikh N, Branch AD. Classical and emerging roles of vitamin D in hepatitis C virus infection. Sem Liver Dis 2011; 31: 387-98.
Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
Cohen ML, Duovdevani A, Chaimovitz C, Shany S. Regulation of THF-alpha by 1alpha,25-dyhydroxyvitamin D3 in human macrophages from CAPD patients. Kidney Int 2001; 59: 69-75.
von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signalling and activation of human T cells. Nat Immunol 2010; 11: 344-9.
Chesney RW. Vitamin D and the magic mountain: the anti-infectious role of the vitamin. J Pediatr 2010; 156: 698-703.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Endocrinol Metab 2011; 96: 1911-30.
Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 513-20.
Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic liver disease. Clin Gastroenterol Hepatol 2007; 5: 513-20.
Miroliaee A, Nasiri-Toosi M, Khalilzadeh O, Esteghamati A, Abdollahi A, Mazloumi M. Disturbances of parathyroid hormona- vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int 2010; 4: 634-40.
Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, Herrman E, et al. Vitamin D deficiency and CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferonalfa based therapy. J Hepatol 2011; 54: 887-93.
Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, Poynard T, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 756-61.
Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-67.
Bitetto D, Fattovich G, Fabris C, Ceriani A, Falleti E, Fornasiere E, Pasino M, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118-26.
Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, Bignulin S, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transpl Int 2011; 24: 43-50.
Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina A-R, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011; 17: 5184-90.
Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother 2007; 51: 2016-27.
Yano M, Ikeda M, Abe K, Kawai Y, Kuroki M, Mori K, Dansako H, et al. Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase. Hepatology 2009; 50: 678-88.
Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54: 1570-9.
Agúndez JA, García-Martín E, Maestro ML, Cuenca F, Martinez C, Ortega L, Carballo M, et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. Plos One 2012; 7: e37998.
Hochwald O, Harman-Boehm I, Castel H. Hipovitaminosis D among inpatients in a sunny country. Isr Med Assoc J 2004; 6: 82-7.
González-Molero I, Morcillo S, Valdés S, Pérez-Valero V, Botas P, Delgado E, Hernández D, et al. Vitamin D deficiency in Spain: a population-based cohort study. Eur J Clin Nutr 2011; 65: 321-8.
Mezquita-Raya P, Muñoz-Torres M, Luna Juan D, Luna V, López-Rodríguez F, Torres-Vela E, Escobar-Jiménez F. Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Min Res 2001; 16: 1408-15.
Ladero JM, García-Martín E, Fernández C, Carballo M, Devesa MJ, Martinez C, Suárez A, et al. Predicting response to therapy in chronic hepatitis C: an approach combining IL28B polymorphisms and clinical data. J Gastroenterol Hepatol 2012; 27: 279-85.